References
- Balogh LP. Why do we have so many definitions for nanoscience and nano-technology? Nanomedicine6, 397–398 (2010).
- Ehrlich P. [On the current state of the art of chemotherapy.] Ber. Dtsch Bot. Ges.42, 17–47 (1909).
- Ehrlich P. Partial cell functions: Nobel lecture, December 11, 1908. In: Physiology or Medicine: Including Presentation Speeches and Laureates’ Biographies 1901–1921.Elsevier, Amsterdam, The Netherlands, 304–320 (1967).
- Rannarda S, Owen A. Nanomedicine: not a case of ‘‘one size fits all’’. Nano Today4, 382–384 (2009).
- Stern ST, McNeil SE. Nanotechnology safety concerns revisited. Toxicol. Sci.101, 4–21 (2008).
- Minchin R. Sizing up targets with nanoparticles. Nature Nanotechnol.3, 12–13 (2008).
- Jennings GT, Bachmann MF. Designing recombinant effective vaccines with viral properties: a rational approach to more effective vaccines. Curr. Mol. Med.7, 143–155 (2007).
- Kostarelos K, Miller AD. Synthetic, self-assembly ABCD nanoparticles; a structural paradigm for viable synthetic non-viral vectors. Chem. Soc. Rev.34, 970–994 (2005).
- Kaba SA, Brando C, Guo Q et al. A nonadjuvanted polypeptide nanoparticle vaccine confers long-lasting protection against rodent malaria. J. Immunol.183, 7268–7277 (2009).
- Noad R, Roy P. Virus-like particles as immunogens. Trends Microbiol.11, 438–444 (2003).
- Akira S, Takeda K. Toll-like receptor signalling. Nat. Rev. Immunol.4, 499–511 (2004).
- Heuking S, Adam-Malpel S, Sublet E, Iannitelli A, di Stefano A, Borchard G. Stimulation of human macrophages (THP-1) using Toll-like receptor-2 (TLR-2) agonist decorated nanocarriers. J. Drug Target.17, 662–670 (2009).
- Schlosser E, Mueller M, Fischer S et al. TLR ligands and antigen need to be coencapsulated into the same biodegradable microsphere for the generation of potent cytotoxic T lymphocyte responses. Vaccine13, 1626–1637 (2008).